BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20261002T083000
DTEND;TZID=Europe/Stockholm:20261002T163000
DTSTAMP:20260911T115249Z
CREATED:20260316T134245Z
LAST-MODIFIED:20260911T115249Z
UID:10001772-1790929800-1790958600@www.scilifelab.se
SUMMARY:AI Frontiers in Life Sciences: From Models to Meaning
DESCRIPTION:Image by Andreas Bergfeldt                         \n\n\n\nDate and time: October 2\, 2026 at 8.30-16.30 CET \n\n\n\nLocation: Humanistiska teatern – Uppsala\, onsite and livestream via Zoom \n\n\n\nThe AI Frontiers in Life Sciences: From Models to Meaning symposium will bring together experts in artificial intelligence (AI) and life sciences to explore emerging directions\, challenges\, and opportunities for AI in life science research. \n\n\n\nThe symposium will feature presentations\, demonstrations\, and panel discussions with leading international and Swedish experts. The event is intended for researchers\, infrastructure experts\, and professionals interested in AI-driven life science research. Discussions will also provide input to the continued development of the SciLifeLab AI Strategy and ongoing and planned activities across SciLifeLab. \n\n\n\nFurther details\, including the full programme\, will be announced soon. \n\n\n\nRegistration: \n\n\n\nRegistration \n\n\n\nParticipation is free of charge and places are allocated on a first-come\, first-served basis. Refreshments and lunch will be provided for on-site participants. \n\n\n\nIn-person places are limited. If in-person registration is full\, you are welcome to join the waiting list or register to attend the event via the Zoom livestream. \n\n\n\nIf you register to join the talks via Zoom\, you will receive the livestream link on the day of the event. Please note that the talks will be streamed live only and will not be recorded or made available afterwards. \n\n\n\nRegister Here\n\n\n\nWaiting List \n\n\n\nIf we reach full capacity for in-person attendance\, a waiting list will be activated. If you join the waiting list\, you will automatically receive an email if a place becomes available. \n\n\n\nYou will need to accept the offer to secure your place. If you decline\, the place will be offered to the next person on the waiting list. \n\n\n\nCancellation \n\n\n\nTo help us minimise empty seats and food waste\, please cancel your registration if you are no longer able to attend the event. If a waiting list is active\, this will allow us to offer your place to another participant. Timely cancellations also help us avoid unnecessary costs for refreshments and lunch. \n\n\n\nIf you have questions\, please contact datacentre@scilifelab.se \n\n\n\nSpeakers: \n\n\n\nAnna Kreshuk\, EMBL\nInterim Head of Cell Biology and Biophysics Unit \n\n\n\nAnna Kreshuk is a Group Leader and Senior Scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg\, where she develops computer vision methods for the analysis of microscopy images. She contributes to open-source tools including ilastik and PlantSeg and is an ELLIS Scholar and scientific co-coordinator of the Horizon Europe project AI4Life. She has served as Interim Head of EMBL’s Cell Biology and Biophysics Unit since 2024. \n\n\n\nWeb: Kreshuk Group \n\n\n\n\nFlorian Jug\, Human Technopole\nHead of Computational Biology Research Centre – Multimodal AI Across Scales\, Computational biology\, Research Group Leader\,  \n\n\n\nDr. Florian Jug holds a PhD in Computational Neuroscience from the Institute of Theoretical Computer Science at ETH Zurich. His research aims at pushing the boundary of what AI and machine learning can do to better analyze and quantify biological data. At HT\, Dr. Jug covers the full breadth of bio-image computing\, from research on novel methods for computer vision and machine learning\, all the way to offering bio-image analysis as a service.  \n\n\n\nWeb: Jug Group \n\n\n\n\nHeidi Howard\, Chalmers University of Technology & SciLifeLab\nBioethicist and ELSI Lead \n\n\n\nHeidi Howard is a bioethicist and ELSI (Ethical\, Legal and Social Issues) Lead at SciLifeLab and the Data-Driven Life Science (DDLS) programme. Her work focuses on the ethical\, legal and social implications of data-driven life science and AI\, with experience in AI ethics\, policy and safety. \n\n\n\n\nKadi Liis Saar\, Recursion\nScientific Leader and Associate Principal Scientist\, Recursion\, a company focused on AI-driven solutions in drug discovery. \n\n\n\nDr. Kadi Liis Saar is the Scientific Leader and Associate Principal Scientist\, Computational Biology & Data Science at Recursion\, and elected member of Estonian Young Academy of Science. Dr. Saar is an interdisciplinary scientist and inventor with a background in chemical engineering and biotechnology (BA & MEng) and biophysical chemistry (PhD University of Cambridge 2018). Previously at Transition Bio\, she was a Junior Research Fellow at St. John’s College\, University of Cambridge and a Schmidt Science Fellow working between the Centre for Misfolding Diseases and the Maxwell Centre 2018-2022.  \n\n\n\nWeb: Recursion \n\n\n\n\nSamuel Kaski\, ELLIS Institute Finland\nFounding Director\, ELLIS Institute Finland \n\n\n\nSamuel Kaski is the founding director of ELLIS Institute Finland and leads the Finnish Center for Artificial Intelligence (FCAI). He is Professor of Machine Learning at Aalto University and Professor of Artificial Intelligence at the University of Manchester. His research focuses on probabilistic machine learning and collaborative AI\, with applications in health\, medicine and biology. \n\n\n\nWeb: Kaski Lab \n\n\n\n\nSebastian Lobentanzer\, Helmholtz Center Munich \nPrincipal Investigator\, Computational Health Center \n\n\n\nSebastian Lobentanzer is a PI at the Computational Health Center at Helmholtz Center Munich since 2025\, and in affiliation with the Open Targets group at the European Bioinformatics Institute (EMBL-EBI) since 2024. Sebastian serves as the head of computational biology at the German Center for Diabetes Research. He is the author of BioCypher – https://biocypher.org/ \, BioChatter – https://biochatter.org/ projects. \n\n\n\nWeb: Lobentanzer Lab \n\n\n\n\nSymposium Programme \n\n\n\n\n\n\n\nHumanistiska teatern \n\n\n\n\n\n\n\n\n\n\n\n\n\nOrganisers: SciLifeLab Data Centre datacentre@scilifelab.se
URL:https://www.scilifelab.se/event/ai-frontiers-in-life-sciences-from-models-to-meaning/
LOCATION:Humanistiska teatern\, Uppsala\, Thunbergsvägen 3C\, Uppsala\, 75238\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2026/03/AI-Frontiers-Feature-Image.png
ORGANIZER;CN="SciLifeLab Data Centre":MAILTO:datacentre@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20261012T120000
DTEND;TZID=Europe/Stockholm:20261014T120000
DTSTAMP:20260507T093008Z
CREATED:20260414T090237Z
LAST-MODIFIED:20260507T093008Z
UID:10001802-1791806400-1791979200@www.scilifelab.se
SUMMARY:WASP-HS & DDLS: Interdisciplinary Workshop
DESCRIPTION:WASP-HS & DDLS: Joint Workshop at Sigtunastiftelsen\, 12–14 October \n\n\n\nThis interdisciplinary workshop brings together a carefully selected group of 25 researchers from diverse fields to exchange perspectives on the ethical\, legal\, and social dimensions of data-intensive research in the life sciences. The conversation is not limited to lawyers and ethicists\, but also includes researchers whose work both shapes and is shaped by these governance frameworks.  \n\n\n\nThe aim is to bring together diverse expertise to explore key challenges\, frame shared research questions\, and spark new interdisciplinary collaborations. \n\n\n\nWorkshop Focus\n\n\n\n→ Analyze governance structures and how they shape data-intensive research in precision medicine\, epidemiology\, infection biology\, biodiversity\, and molecular life sciences→ Identify key legal\, regulatory\, and ethical challenges in data-driven life sciences\, with particular attention to the experiences of scientists working with these issues in practice→ Promote meaningful dialogue across disciplines→ Develop new interdisciplinary research initiatives \n\n\n\nDuration\n\n\n\n12 OctoberArrival and opening from lunch onwards \n\n\n\n13 OctoberFull day of sessions \n\n\n\n14 OctoberClosing and departure ending with lunch  \n\n\n\nExpression of Interest\n\n\n\nApply by May 14 to secure your spot. This workshop is open to researchers from both the WASP-HS and DDLS communities. Spots are limited to 25 participants\, so make sure to fill in the Expression of Interest form to get a chance to attend. \n\n\n\nApply here \n\n\n\nOrganizers\n\n\n\nLianne Colonna\,WASP-HS\, Stockholm UniversityYana Litins’ka\, WASP-HS\, Lund UniversityHeidi Howard\, DDLS\, Chalmers University of TechnologyFrancis Lee\, WASP-HS\, Södertörn UniversityUlrika Wallenquist\, DDLS\, Uppsala UniversityBodil Formark\,WASP-HS\, Södertörn University
URL:https://www.scilifelab.se/event/wasp-hs-ddls-interdisciplinary-workshop/
LOCATION:Sigtunastiftelsen\, Manfred Björkquists allé 4\, Sigtuna\, 193 31\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2025/11/DDLS.jpg
ORGANIZER;CN="Data-Driven Life Science @ SciLifeLab":MAILTO:ddls@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20261013T090000
DTEND;TZID=Europe/Stockholm:20261013T183000
DTSTAMP:20260909T100640Z
CREATED:20251219T143433Z
LAST-MODIFIED:20260909T100640Z
UID:10001690-1791882000-1791916200@www.scilifelab.se
SUMMARY:The PROMISE Initiative: Accelerating Cancer Innovation
DESCRIPTION:This conference focuses on the PROMISE Cancer effort led by Swedish scientists representing Stockholm\, Uppsala\, Umeå\, Linköping\, Lund\, and Gothenburg as well as SciLifeLab. \n\n\n\nCancer encompasses more than 200 distinct diseases\, each with widely varying prognoses\, ranging from highly treatable to aggressive cancers with poor outcomes. Advances in molecular profiling hold great promise for improving diagnostics and treatment by enabling more precise\, personalized approaches tailored to individual patients. Sweden has world-leading cancer registries and high-quality biobanks\, creating unique opportunities for cancer research. By joining forces across the research community\, we can better leverage these national strengths to benefit patients. SciLifeLab platforms support the generation\, integration\, and analysis of data across genomics and a broad range of other omics technologies. \n\n\n\nThe goal of the conference is to expand the PROMISE Cancer initiative\, promote its efforts\, and continue building the Swedish cancer community. \n\n\n\nRegistration\n\n\n\nRegister here\n\n\n\nAbout PROMISE\n\n\n\nPrecision Omics Initiative Sweden (PROMISE) is a national initiative using genomics and multiomics to understand common diseases\, rare diseases\, and cancer. \n\n\n\nRead more about PROMISE\n\n\n\nProgram and speakers\n\n\n\n\n\n\n\nMike Stratton\, Sanger Institute\nMike Stratton qualified in medicine at Oxford University and Guy’s Hospital Medical School and obtained a PhD in the Molecular Biology of Cancer at the Institute of Cancer Research\, London. His research into the genomes of normal and cancer cells includes discovery of the breast cancer susceptibility gene BRCA2\, of somatically mutated BRAF in malignant melanoma\, and establishing the conceptual and analytic framework of mutational signatures. He is a Fellow of the Royal Society\, an International Member of the US National Academy of Sciences and was Knighted in the 2013 Queen’s birthday honours. \n\n\n\n\nThoas Fioretos\, Lund University\nThoas Fioretos\, MD\, PhD\, is Professor of Clinical Genetics at Lund University and Senior Consultant at Skåne University Hospital. His research focuses on the molecular basis of acute leukemia and its translation into improved diagnostics and targeted therapies. His group applies genomic and single-cell approaches to define cell states\, stem-cell properties\, immune-evasion mechanisms and cell-surface targets. The group was among the first to establish IL1RAP as a therapeutic target on leukemia stem cells and recently identified SLAMF6 as an immune checkpoint in acute myeloid leukemia. These discoveries have supported antibody-based therapies\, including an investigator-initiated trial evaluating an IL1RAP-targeting antibody in AML and high-risk MDS at MD Anderson Cancer Center. Fioretos is a Wallenberg Clinical Scholar\, Platform Scientific Director of Clinical Genomics Lund at SciLifeLab and a founding member of Genomic Medicine Sweden. He is a member of the Royal Swedish Academy of Sciences and currently chairs its Class for Medical Sciences. \n\n\n\n\nShahar Alon\, Bar-Ilan University\nDr. Shahar Alon leads the Spatial Genomics lab at the Faculty of Engineering\, Bar-Ilan University. Dr. Alon background is in Physics and Neuroscience\, with a PhD from Tel Aviv University\, and a postdoc in the group of Prof. Ed Boyden at MIT. Dr. Alon was awarded the LSRF scholarship during his postdoc and the ERC starting grant as a principal investigator. Alon’s group research questions are mainly related to RNA localization in neurons in healthy and disease-related tissues as well as in cancer tissues. Alon’s group builds technologies and data analysis tools for spatial single cell analysis. \n\n\n\n\nEsther Rheinbay\, Harvard Medical School\nEsther Rheinbay is an Assistant Professor of Medicine at Harvard Medical School and a Principal Investigator at the Krantz Family Center for Cancer Research at Massachusetts General Hospital. She is also an Associate Member of the Broad Institute of MIT and Harvard. Dr. Rheinbay’s research focuses on the intersection of cancer genomics and epigenomics\, with a particular interest in understanding how non-coding mutations and large-scale chromosomal alterations drive tumor progression. Her group is also interested in the role of the sex chromosomes\, and specifically the Y chromosome in cancer. Dr. Rheinbay earned her undergraduate degree in Bioinformatics from the University of Tübingen and her Ph.D. from Boston University\, where she specialized in computational epigenomics. She completed her postdoctoral training at the Broad Institute. Beyond the lab\, Dr. Rheinbay is an advocate for supporting parent scientists in academia\, and enjoys teaching the creativity of designing effective scientific figures. \n\n\n\n\nKarin Forsberg Nilsson\, Uppsala University\nKarin Forsberg-Nilsson is Professor of Stem Cell Research at Uppsala University\, Sweden\, and a SciLifeLab Group Leader. She received her PhD from Uppsala University in 1992 followed by a postdoc at the National Institutes of Health\, USA. Alongside her research\, she has held leadership positions in the pharma/biotech sector\, the Swedish Research Council\, SciLifeLab\, and Uppsala University\, most recently serving as Dean of the Faculty of Medicine. Her research focuses on the intersection of cancer and neurobiology\, combining neural stem cell biology with expertise in brain tumor biology and genetics. Her laboratory investigates non-coding mutations in brain tumors\, with a particular focus on regulatory regions under evolutionary constraint. This work is based on the hypothesis that conserved genomic regions are more likely to be functional and that mutations within them may have greater biological impact. \n\n\n\n\nMargareta Haag\, Swedish Network Against Cancer\nMargareta Haag is Chair of the Swedish Network against Cancer\, an umbrella organization for cancer patient organizations and their families. A lymphoma patient since 1994 and a lymphoedema patient since 1995\, she is a strong patient representative and advocate. She is former Executive Director of an international professional body and the Federation of Biomedical Laboratory Science. Her leadership roles include President of the Swedish Association of Chronic Oedema and former member of the Swedish Ministry of Social Affairs’ Patient Advisory Council (2019–2021). Margareta has also contributed to the Government’s Innovation Partnership Programme in Health and Life Science\, focusing on precision medicine and ATMPs. She serves or has served on several patient and health-related boards and advisory groups\, including All.Can Sweden\, GPCC\, EUPATI Sweden\, Agenda for Health and Well-being\, Research Sweden\, Patient Advocacy 2.0\, and Zero Vision Cancer. \n\n\n\n\nAnn Nordgren\, Karolinska Institutet\n \n\n\n\n\nJohan Lindberg\, Karolinska Institutet\nJohan Lindberg is Principal Researcher at the Department of Medical Epidemiology and Biostatistics\, Karolinska Institutet. His research covers cancer genomics\, bioinformatics\, assay development\, biomarker discovery\, and clinical trials. He has established an infrastructure and a team that performs prospective genomic analysis of cancer genomes and delivers results within a clinically relevant timeframe. More than 6500 reports have been sent to approximately 50 hospitals in six European countries. He is responsible for the prospective genomic analysis in the ProBio Biomarkers trial (NCT03903835)\, an outcome-adaptive randomised platform trial in metastatic prostate cancer (Nature Medicine\, 2024)\, and held the same responsibility in the ALASCCA trial which evaluated low-dose aspirin in PI3K-altered localised colorectal cancer (New England Journal of Medicine\, 2025). Assays developed in these programmes are currently in routine diagnostic use at Karolinska University Hospital for metastatic prostate cancer and six further diagnoses. \n\n\n\n\nOlli Kallioniemi\, Institute for Molecular Medicine Finland (FIMM)\nOlli Kallioniemi is Research Director at the Institute for Molecular Medicine Finland (FIMM)\, part of HiLIFE at the University of Helsinki. He earned his MD (1985)\, PhD (1988)\, and specialization in Clinical Chemistry (1990) from the University of Tampere. He then spent 11 years in the U.S. as a postdoctoral fellow at UCSF and tenure-track investigator at NHGRI/NIH\, where he was tenured in 2001. From 2007–2015\, he served as the founding director of FIMM in Helsinki\, later recruited to Sweden to direct the Science for Life Laboratory (SciLifeLab) in 2015–2024\, Sweden´s national life science research infrastructure\, as well as nominated to a professorship in molecular precision medicine at Karolinska Institutet. He also acted as the Founding Director of the 3.3B SEK SciLifeLab-KAW Data-Driven Life Science (DDLS) program. His research focuses on AI- and data-driven precision medicine\, particularly in acute myeloid leukemia and prostate cancer\, and he co-leads a national initiative to plan the future of Finnish health data space and its utilization. He has authored 420+ publications\, holds ~20 patents\, and supervised 27 doctoral theses and over 30 postdocs. His honors include the Anders Jahre Young Investigator Award\, Äyräpää Prize\, AACR Team Science Awards\, and Biomedicum Medal. He is a member of EMBO\, the European Academy of Cancer Sciences\, the Royal Swedish Academy of Sciences\, and the Nobel Assembly at Karolinska Institutet. \n\n\n\n\nBerend Snijder\, Institute of Molecular Systems Biology\, ETH Zürich\nBerend Snijder is a Faculty Member at the Botnar Institute of Immune Engineering. He is a group leader at the Swiss Institute of Bioinformatics and the Comprehensive Cancer Center Zurich\, and was previously Assistant Professor at the Institute of Molecular Systems Biology at the ETH Zurich. Berend’s research focuses on the systematic functional and multi-omic profiling of human tissues in health and disease\, with strong bioinformatics and clinical/translational focus. He is a leading figure in the field of functional precision medicine. Berend has co-founded three spinoff companies\, including Allcyte (acquired by Exscientia\, now Recursion)\, Prevision Medicine\, and Graph Therapeutics. \n\n\n\n\nTuuli Lappalainen\, KTH & New York Genome Center\nTuuli Lappalainen\, PhD\, is a Professor at KTH Royal Institute of Technology\, the Director of the Genomics Platform and the National Genomics Infrastructure of SciLifeLab\, Sweden\, and a Senior Associate Faculty Member at the New York Genome Center. Dr. Lappalainen received her PhD in Genetics from the University of Helsinki. Her research focuses on molecular and cellular effects of genetic variation in human populations and their contribution to human traits and diseases. She has contributed to many international research consortia in human genetics\, and she has received multiple prizes for her contributions to the field. \n\n\n\n\nTobias Sjöblom\, Uppsala University\nTobias Sjöblom is Professor of Tumor Genetics at Uppsala University\, Sweden. His current research interests include the somatic genetic basis of colorectal cancer\, phenotypes of cancer mutations\, and diagnostics and therapeutics development based on somatic mutations. He is Program Director for U-CAN\, a longitudinal cancer research initiative encompassing >30.000 patients to support cancer biomarker research. \n\n\n\n\nLao Saal\, Lund University\nDr. Lao Saal\, MD/PhD\, is Head of Translational Oncogenomics\, Division of Oncology\, at Lund University\, and is the Co-Director of the CIRCE Women’s Cancer Research Center and Head of SCAN-B Translational Research. He was also founder and CEO of SAGA Diagnostics\, a spinout company from his laboratory that focused on circulating tumor DNA liquid biopsy testing\, and which was acquired by Foundation Medicine / Roche for up to 595 MUSD\, and is the consulting Medical Director for the AI digital pathology company DoMore Diagnostics. Dr. Saal has MD and PhD degrees from Columbia University (New York) and has trained at the U.S. National Institutes of Health and Memorial Sloan Kettering Cancer Center\, and has published more than 80 articles\, including in leading journals such as Nature Genetics\, Science\, and PNAS\, which in total have been cited more than 15\,000 times. \n\n\n\n\nJohanna Sandgren\, Karolinska Institutet\nJohanna Sandgren\, PhD\, is Director of the Swedish Childhood Tumour Biobank at Karolinska Institutet and Karolinska University Hospital in Stockholm\, Sweden. She serves on the coordinating group of Genomic Medicine Sweden Childhood Cancer and the operational leadership group of the BrainChild initiative led by the Swedish Childhood Cancer Fund. She also currently contributes to the reference group for implementation of a digital biobank application system developed by Biobank Sverige. Dr. Sandgren earned her PhD in Cancer Genomics from Uppsala University and has more than 15 years of experience in the area of pediatric cancer research. The focus now\, and for almost 10 years\, is on facilitate the advancing of childhood cancer research\, and care\, through the research infrastructure Swedish Childhood Tumour Biobank (Barntumörbanken). This by enabling controlled access to population-based collection of high-quality biospecimens\, harmonized OMICS and meta data\, as well as via collaborations and services that support both research and clinical studies. \n\n\n\n\nAndreas Josefsson\,	Umeå University\nAndreas Josefsson\, MD\, PhD\, is Associate Professor and Senior Consultant in Urology at Umeå University and Norrland University Hospital. His research focuses on prostate cancer\, particularly high-risk and metastatic disease\, combining clinical studies with translational work on tumour biology and biomarkers. He is principal investigator and chair of SPRINTR (Swedish PRecision medicine Initiative for Novel Treatments and Research)\, a national prospective platform in which patients are enrolled in routine care\, with structured clinical data\, molecular profiling\, imaging\, digital pathology\, possibility for biobanking\, and linkage to national registries. SPRINTR started in prostate cancer\, includes all seven Swedish university hospitals and several more sites\, and serves as a study-ready population for translational research and clinical trials. The concept is now being extended to other cancer types. He is also a member of the steering groups of Umeå Comprehensive Cancer Center\, the National Prostate Cancer Register\, and the Scandinavian Prostate Cancer Group. \n\n\n\n\nScientific committee\n\n\n\n\n\n\n\nProject manager\n\n\n\nAnna Clareborn \n\n\n\nEvent Sponsors\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYou may also be interested in\n\n\n\n\nSciLifeLab Science Summit
URL:https://www.scilifelab.se/event/the-promise-initiative-accelerating-cancer-innovation/
LOCATION:Lecture Hall X\,  University Main Building\, Uppsala\, Biskopsgatan 3\, Uppsala\, 75105\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/12/Promise-Sweden-Banner-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20261014T084500
DTEND;TZID=Europe/Stockholm:20261014T170000
DTSTAMP:20260911T060729Z
CREATED:20251219T121224Z
LAST-MODIFIED:20260911T060729Z
UID:10001689-1791967500-1791997200@www.scilifelab.se
SUMMARY:SciLifeLab Science Summit
DESCRIPTION:The Annual Conference SciLifeLab Science Summit is a one-day symposium with a new topic each year. The 2026 topic is: \n\n\n\nCancer Research: Translating Life Science Discoveries to Clinical Breakthroughs\n\n\n\nFor more than a century\, Swedish cancer research has shaped the international scientific landscape\, driven by strong academic environments and a deep societal commitment to transforming discoveries into better treatments. From breakthroughs in cancer genomics and tumor biology to advances in immunology and angiogenesis\, researchers in Sweden continue to push the boundaries of life science and medicine. \n\n\n\nThe SciLifeLab Science Summit brings this legacy into the future by uniting world-leading cancer researchers with cutting-edge technologies across genomics\, proteomics\, imaging\, data science\, and beyond. The summit creates an inspiring forum where scientific excellence meets societal relevance—fostering collaboration\, showcasing groundbreaking research\, and highlighting how cancer research continues to reveal fundamental mechanisms of life while driving innovation with real-world impact. \n\n\n\nThe conference is free of charge. Fika\, lunch and Meet-the-speaker-mingle will be included (only) if you register before deadline on September 21. \n\n\n\nJoin us for a full day of inspiring Science! \n\n\n\nWelcome! \n\n\n\nScientific Committee\n\n\n\n\n\n\n\nProject leader: Erika Erkstam\, Operations Office\, SciLifeLab \n\n\n\nRegistration\n\n\n\nDeadline (for registration and posters): September 21 \n\n\n\nQuestions? If you have any inquiries regarding the event or your registration\, please contact events@scilifelab.se \n\n\n\nFor late registrations (after September 21)\, we cannot guarantee lunch\, coffee\, nor can we accommodate any allergies or dietary requirements. These will be subject to availability. We appreciate your understanding. \n\n\n\nRegister here\n\n\n\n\n\n\n\n\n\n\n\nSpeakers\n\n\n\n\nAngelica Loskog\, Uppsala University and Lokon Pharma\n\n\n\nAnna Martner\, University of Gothenburg\, Sweden\n\n\n\nAri Molofsky\, University of California\, San Francisco\, US\n\n\n\nBernd Bodenmiller\, University of Zurich and ETH Zurich\, Switzerland\n\n\n\nGabriele Bergers\, VIB-KU Leuven Center for Cancer Biology\, Belgium\n\n\n\nGunilla Edblad\, Uppsala University and Uppsala University Hospital\n\n\n\nGöran B. Jönsson\, Lund University\n\n\n\nIñaki Martin-Subero\, ICREA Research Professor at IDIBAPS\, Barcelona\, Spain\n\n\n\nThoas Fioretos\, Lund University\n\n\n\n\nProf. Angelica Loskog\nUppsala University\, Sweden and Lokon Pharma. \n\n\n\nTitle: Evoking Tumor Immunity in Immune-Resistant Cancers  \n\n\n\nAbstract:  \n\n\n\nGrauers Wiktorin H1\, Lövgren T1\, Wenthe J1\, Ritter A1\, Calandegary A1\, Ekström Ryden V\,1\,2 Hahn A1\,2\, Hamid O3\, Gustafsson Liljefors M4\, Musher BL5\, Brenner MK5\, Ullenhag G1\,2\, Loskog A1\,6. \n\n\n\n1Uppsala University\, Uppsala\, Sweden \n\n\n\n2Uppsala University Hospital\, Uppsala\, Sweden \n\n\n\n3The Angeles Clinic and Research Institute\, A Cedars Sinai Affiliate\, Los Angeles\, CA\, USA \n\n\n\n4Karolinska Hospital\, Huddinge\, Sweden \n\n\n\n4Baylor College of Medicine\, Houston\, TX\, USA \n\n\n\n6Lokon Pharma AB\, Uppsala\, Sweden \n\n\n\nImmunotherapy for cancer is a cornerstone of cancer treatment but despite the initial success\, many patients are either primary resistant or develop resistance during treatment. By engineering the tumor microenvironment using and oncolytic adenoviral gene vector encoding TMZ-CD40L and 4-1BBL (LOAd703)\, we aim to rewire the immunosuppressive state in the patients to drive anti-tumor immune responses allowing for continued immune checkpoint inhibitor (ICI) treatment of refractor patients and/or ICI treatment of indications previously not responding to ICI. LOAd703 plus ICI have been tested in melanoma patients (n=24) refractory to one or several lines of prior ICI\, and in pancreatic cancer patients (LOAd703 +standard chemotherapy\, n=21; LOAd703 + ICI + standard chemotherapy\, n=24) who are commonly not responding to ICI. In these Phase I/II clinical trials blood and biopsies were analyzed for the initiation of immune responses locally in the tumor microenvironment as well as systemically in blood. \n\n\n\nThe treatment was well tolerated with common adverse events related to chemotherapy (pancreatic cancer) or ICI (melanoma and pancreatic cancer). LOAd703 attributed adverse events included fever\, chills\, and cytokine release syndrome\, mostly grade 1 or 2. Both in melanoma and pancreatic cancer\, LOAd703 promoted a typical Th1 type of immune response post treatment initiation which was noted both in the tumor and in blood. Similarly\, tumor responses were noted in both indications as evaluated with Olink proteomics\, NanoString Technology\, and flow cytometry. In conclusion\, LOAd703 can be used together with chemotherapy and/or ICI treatment to rewire the immunosuppressive state in patients towards Th1 immunity and subsequently controlling tumor growth in patients. \n\n\n\n \n\n\n\n\nProf. Anna Martner\nUniversity of Gothenburg\, Sweden.  \n\n\n\nTitle: NOX2-derived ROS as drivers of metastatic progression \n\n\n\nBiosketch: Anna Martner is a group leader at the Sahlgrenska Center for Cancer Research\, University of Gothenburg. Her research focuses on myeloid cell-mediated immunosuppression\, NOX2-derived ROS\, tumor cell plasticity\, and metastasis. She trained with Professors Kristoffer Hellstrand and Dmitry Gabrilovich and spent a 2019 sabbatical in Professor Robert Weinberg’s laboratory at MIT studying EMT. \n\n\n\nAbstract: The efficacy of cancer immunotherapy depends on the balance between anti-tumor effector cells\, including natural killer (NK) cells and T cells\, and mechanisms of tumor-associated immunosuppression. Inflammatory myeloid cells\, including myeloid-derived suppressor cells (MDSCs)\, contribute to immune evasion through several mechanisms\, among them the production of reactive oxygen species (ROS) by NOX2. \n\n\n\nOur group investigates the role of NOX2-derived ROS in cancer-associated immunosuppression and metastasis\, and the potential of targeting this pathway therapeutically. We have shown that genetic or pharmacological inhibition of NOX2 promotes NK cell-mediated clearance of metastatic tumor cells and enhances the efficacy of immune checkpoint blockade (Aydin et al.\, Cancer Immunol Res\, 2017; Grauers Wiktorin et al.\, Cancer Immunol Immunother\, 2019). We also found that surgical stress aggravates NOX2-dependent immunosuppression and metastatic progression\, effects that can be counteracted by NOX2 inhibition (Grauers Wiktorin et al.\, Cancer Res Commun\, 2024). \n\n\n\nMore recently\, we found that myeloid cell-derived NOX2-generated ROS can act directly on tumor cells. These ROS induce epigenetic changes that activate epithelial-to-mesenchymal transition (EMT) programs and promote metastasis (Kaya et al.\, PNAS\, 2026). Thus\, NOX2-derived ROS may promote metastatic progression both by suppressing anti-tumor immunity and by enhancing tumor cell plasticity. \n\n\n\nHistamine dihydrochloride (HDC)\, which inhibits NOX2-dependent ROS formation\, is approved in the EU for relapse prevention in acute myeloid leukemia. In an ongoing clinical trial at the Sahlgrenska University Hospital\, we are investigating HDC in combination with IL-2 in patients undergoing surgery for pancreatic cancer\, with the aim of reducing perioperative immunosuppression and metastatic risk. \n\n\n\n\nProf. Ari Molofsky\nUniversity of California\, San Francisco \n\n\n\nTitle: Fibroblast – Immune niches in health and disease. \n\n\n\nBiosketch: Ari Molofsky received a BS with highest honors from the University of Texas at Austin and an MD/PhD with research distinction from the University of Michigan in Ann Arbor. Dr. Molofsky completed residency and fellowship in Clinical Pathology/Hematopathology and now leads a tissue immunology-focused research group in the Department of Laboratory Medicine at UCSF. Dr. Molofsky’s research goals are to understand the regulation and function of tissue-resident immune cells to define novel pathways that can be targeted across diverse human diseases. These tissue-resident immune cells are early organizers of tissue remodeling and first responders during tissue damage and infection\, positioning them as key mediators of tissue health and disease. The Molofsky lab has defined a stromal-immune niche surrounding larger vessels and other border structures in multiple tissues\, including the lungs and brain. They are using 3D quantitative microscopy\, single-cell and spatial transcriptomics\, and cytokine reporters/manipulators to dissect these critical immune-microenvironment interactions\, with a particular focus on bidirectional interactions with fibroblasts. Dr. Molofsky has published papers spanning microbial pathogenesis\, tissue-resident immunity\, and local immune niches. Dr. Molofsky is actively involved in trainee education and teaching and leads the UCSF medical school immunology course. Dr. Molofsky routinely serves as an ad hoc reviewer for multiple journals and is a standing member of the NIH Innate Immunity study section. \n\n\n\nAbstract: \n\n\n\n\nProf. Bernd Bodenmiller\nUniversity of Zurich and ETH Zurich\, Switzerland \n\n\n\nTitle: Highly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometry \n\n\n\nBiosketch: Bernd Bodenmiller is a quantitative biologist who develops novel experimental and computational approaches for the quantitative analysis of tumor ecosystems to improve our understanding of the mechanisms of tumor development for the benefit of patients. He is the founding director of the Department of Quantitative Biomedicine (DQBM) at the University of Zurich\, which fosters research and education at the interface of biomedical research\, biotechnology\, and computational biology to guide development of next-generation precision medicine. Prof. Bodenmiller obtained his PhD in the group of Ruedi Aebersold at ETH Zürich. For his postdoctoral training\, he joined the laboratory of Garry P. Nolan at Stanford University. In 2012\, he became a group leader and in 2013 an SNF/ERC assistant professor at the University of Zürich. In 2019\, he was tenured and became the founding director of the DQBM. In October 2020 Prof. Bodenmiller has been appointed as Dual Professor for Quantitative Biomedicine at the UZH and at ETH Zurich. His group pioneered the development of imaging mass cytometry\, an approach that enables simultaneously imaging of over 40 proteins and transcripts in tumor tissues (Nat. Methods\, 2014; Cell Systems\, 2017; Nature 2020) and the histoCAT software toolbox (Nat. Methods\, 2017). His groups applies these methods to unravel how cells in the tumor ecosystem drive cancer development to identify mechanisms that might be exploited for therapeutic targeting (Nat. Biotechnology\, 2017\, Cell\, 2017; Cell\, 2019). \n\n\n\nAbstract: Cancer is a tissue disease. Heterogeneous cancer cells and normal stromal and immune cells form a dynamic ecosystem that evolves to support tumor expansion and ultimately tumor spread. The complexity of this dynamic system is the main obstacle in our attempts to treat and heal the disease. The study of the tumor ecosystem and its cell-to-cell communications is thus essential to enable an understanding of tumor biology\, to define new biomarkers to improve patient care\, and ultimately to identify new therapeutic routs and targets. \n\n\n\nTo study and understand the workings of the tumor ecosystem\, highly multiplexed image information of tumor tissues is essential. Such multiplexed images will reveal which cell types are present in a tumor\, their functional state\, and which cell-cell interactions are present. To enable multiplexed tissue imaging\, we developed imaging mass cytometry (IMC). IMC is a novel imaging modality that uses metal isotopes of defined mass as reporters and currently allows to visualize over 50 antibodies and DNA probes simultaneously on tissues with subcellular resolution. In the near future\, we expect that over 100 markers can be visualized. We applied IMC for the analysis of breast cancer samples in a quantitative manner. To extract biological meaningful data and potential biomarkers from this dataset\, we developed a novel computational pipeline called histoCAT geared for the interactive and automated analysis of large scale\, highly multiplexed tissues image datasets. Our analysis reveals a surprising level of inter and intra-tumor heterogeneity and identify new diversity within known human breast cancer subtypes as well as a variety of stromal cell types that interact with them.In summary\, our results show that IMC provides targeted\, high-dimensional analysis of cell type\, cell state and cell-to-cell interactions within the TME at subcellular resolution. Spatial relationships of complex cell states of cellular assemblies can be inferred and potentially used as biomarkers. We envision that IMC will enable a systems biology approach to understand and diagnose disease and to guide treatment. \n\n\n\n\nProf. Gabriele Bergers\nVIB-KU Leuven Center for Cancer Biology\, Belgium \n\n\n\nTitle: A vascular perspective on immunity in cancer and inflammation \n\n\n\nBiosketch: Dr. Gabriele Bergers is a Professor of Oncology at the University of Leuven and a Principal Investigator at the Vlaams Instituut Voor Biotechnologie (VIB)-Center for Cancer Biology in Leuven since 2016. Prior\, she followed the faculty rank at the University of California\, San Francisco\, and was a Professor in the Department of Neurological Surgery and a PI in the Brain Tumor Research Center (BTRC) at the Helen Diller Family Comprehensive Cancer Center at the University of California\, San Francisco until 2016. \n\n\n\nThe overall research interest of her group relates to the tumor vasculature\, which entails an integral and critical component of the tumor microenvironment and closely interacts with distinct cell constituents of the heterogeneous tumor community. Such crosstalk is pivotal not only for the genesis and progression of a tumor but also for the tumor’s ability to resist therapeutic elimination. \n\n\n\nOver the last years\, her group has made seminal discoveries in the heterogenous crosstalk of the vascular immune axis and identified several intimate regulatory mechanisms between angiogenesis and immunosuppression that provide novel target possibilities to enhance the effects of cancer therapy by modulating the tumor vascular system and its communication with immune cells; among those\, to induce high endothelial venules and subsequent tertiary lymphoid structures\, with the overarching goal to sensitize and enhance an immune response in cancer patients to thwart tumors and metastases and invigorate tissue homeostasis. \n\n\n\nFor her research\, Dr. Bergers has received several awards\, including the Sidney Kimmel\, the Sandler Opportunity\, UCSF Breakthrough Biomedical Research\, and the Judah Folkman Award. She has acted as an external advisory board member for a number of universities and pharmaceutical companies; most recently for Mestag Therapeutics. Dr. Bergers was the co-director of the U54 Tumor microenvironment Brain Tumor Center at UCSF until 2016. She was  a Scientific co-founder of Oncurious. \n\n\n\nAbstract: The vasculature is a critical gatekeeper of tissue immunity\, determining which cells can enter or exit a tissue. During infection\, specialized endothelial cells known as high endothelial venules (HEVs)become activated to promote lymphocyte entry into lymph nodes\, enabling efficient immune priming against pathogens. In cancer\, however\, the vascular system is frequently reprogrammed to suppress immunity. Tumor endothelial cells can form barriers that limit lymphocyte infiltration\, contributing to immune-cold or immune-desert tumors. At the same time\, tumor cells actively remodel HEVs in tumor-draining lymph nodes\, altering their phenotype to facilitate tumor cell intravasation and systemic dissemination. \n\n\n\nRecent mechanistic insights into HEV regulation reveal that the vascular system can also be therapeutically reprogrammed. Induction of intratumoral HEVs can promote lymphocyte recruitment and the formation of tertiary lymphoid structures (TLS)\, which are associated with stronger anti-tumor immunity and improved clinical outcomes. In contrast\, chronic inflammatory diseases such as psoriasis also display HEV expansion accompanied by persistent T-cell aggregates\, where excessive lymphocyte influx may exacerbate pathology. \n\n\n\nHere\, I will discuss HEVs as central vascular regulators of local and systemic immune responses across cancer and chronic inflammation. I will highlight emerging strategies to modulate the vascular axis to either enhance anti-tumor immunity or dampen pathological inflammation\, positioning HEVs as promising therapeutic targets for restoring tissue immune homeostasis. \n\n\n\n\nProf. Gunilla Enblad\nUppsala University and Uppsala University Hospital \n\n\n\nTitle: CAR T-cells a powerful new immunotherapy \n\n\n\nBiosketch: Gunilla Enblad is professor of oncology at Uppsala university Hospital and Uppsala University and senior consultant in oncology. Her main research interests are lymphomas and CAR T-cells. She was PI for the first two academic CAR T-cell trials in Uppsala\, started already 2014 which was first in Europe. She is now PI for a third academic CAR T-cell trials for lymphomas. She is the chairman of the Swedish CAR T-cell group and co-chairman of SWECARNET\, a collaborative group on CAR T-cells. She is currently performing clinical and translational research on lymphomas and CAR T-cells. \n\n\n\nAbstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed and refractory malignancies and autoimmune disease. CAR T-cells are autologous T lymphocytes genetically modified to express a synthetic receptor targeting a surface antigen on the selected cells i.e. tumor cell or B-cell.. Most clinically approved CAR T-cell products target CD19\, which is widely expressed on B-cell lymphomas and leukemias. Following ex vivo genetic modification and expansion\, the cells are reinfused into the patient to mediate targeted anti-tumor activity. \n\n\n\nClinical studies have demonstrated remarkable efficacy\, with many patients achieving durable remissions and potential cures despite having exhausted conventional treatment options. Uppsala University Hospital pioneered CAR T-cell therapy in Europe\, initiating academic studies in 2014 and contributing to the implementation of CAR T-cells as standard of care in Sweden since 2019. Current research focuses on improving efficacy while reducing treatment-related toxicities\, including cytokine release syndrome\, neurotoxicity\, and immune effector cell-associated hematotoxicity. \n\n\n\nA novel academic phase I study\, CARMA\, evaluates an in-house produced CD20-targeting CAR T-cell armed with a neutrophil activating protein (NAP) derived from Helicobacter pylori. Preliminary results are highly encouraging\, with complete metabolic remissions observed in many evaluable patients and only mild adverse effects. Ongoing translational studies aim to identify biomarkers of response and resistance\, ultimately supporting the development of safer and more effective CAR T-cell therapies. \n\n\n\n\nProf. Göran Jönsson\nLund University \n\n\n\nTitle: Exploring the role of the anti-tumor immune response in tumor initiation and therapy response in melanoma \n\n\n\nBiosketch: Göran Jönsson is a professor in molecular oncology at Lund University. His research has for many years been based on strong collaboration between basic- and clinician scientists in truly translational projects. Considering this and his background in state-of-the art genomic technologies and applying that on human melanoma tissue puts him in a perfect position to conduct research that will generate groundbreaking findings. This is further substantiated by the group’s publication in Nature (2020). Göran is a faculty member of ESMO (European Society of Medical Oncology) and have an extensive international network. He is frequently invited to large international meetings and acts as a reviewer to several funding agencies and high-impact journals such as Nature. Göran has also been the recipient of Young and Senior Investigator Awards from the Swedish Cancer Society and more recently was awarded with the Göran Gustafsson prize in medicine 2022 from the Royal Swedish Academy of Sciences and Cancer Researcher of the year (2023) from the Swedish Cancer Society. \n\n\n\nAbstract: \n\n\n\n \n\n\n\n\nProf. Iñaki Martin-Subero\nICREA Research Professor at IDIBAPS\, Barcelona\, Spain \n\n\n\nTitle: Epigenetic memory in chronic lymphocytic leukemia: decoding the past predicts the future \n\n\n\nBiosketch: In 2001\, I obtained my PhD in Biochemistry from the University of Navarra on genetics of lymphoid neoplasms under the supervision of Prof. Maria J Calasanz and co-supervision of Prof. Reiner Siebert from the Christian-Albrechts University of Kiel. After that\, I continued my studies on lymphoma genetics as postdoctoral fellow with Prof. Siebert. In 2005\, I became interested in the field of epigenomics and in 2009 I came back to Spain. After a short stay at the IDIBELL\, I went to the UB/IDIBAPS to start my career as independent researcher embedded in the group of Prof. Elias Campo. In 2016\, I was appointed Junior Leader of the Biomedical Epigenomics group at the IDIBAPS and from November 2018 I am ICREA Research Professor at the IDIBAPS. I also have an appointment as associate professor at the UB. Our group is interested in the role of epigenetics in the origin\, evolution and clinical manifestations of lymphoid tumors. \n\n\n\nAbstract: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in the Western world. Its clinical behavior is extremely variable\, ranging from cases that regress spontaneously without treatment to cases that transform to aggressive lymphomas with short median survival\, a condition called Richter transformation. Such clinical heterogeneity is partially associated with genetic features\, although predicting the future clinical evolution of CLL patients is still challenging. During the last decade\, we have also been investigating the CLL epigenome. We have observed that CLL cells carry DNA methylation imprints of their cellular origin allowing the distinction of three clinical subtypes derived from B cells at different maturation stages. Additionally\, DNA methylation changes in late replicating regions accumulate as cancer cells divide\, allowing the development of a mitotic clock that is able to trace the proliferative history of cancer cells. Furthermore\, using CpG sites with fluctuating methylation\, it is now possible to decode the evolutionary dynamics of CLL development. These aspects of epigenetic memory are strongly associated with disease progression. Studying the transition from CLL to Richter transformation from a multiomics perspective\, we detected that progression was accompanied by the expected increase in complexity of several molecular layers. However\, a detailed genomics and transcriptomics examination at the single cell level revealed that the Richter-associated subclone was present in minute amounts already at the time of diagnosis\, up to two decades before transformation. Overall\, these studies and additional unpublished data presented in the meeting\, indicate that molecular imprints of the past are useful markers to estimate the future clinical behavior of the patients. \n\n\n\n\nProf. Thoas Fioretos\nLund University \n\n\n\nTitle: From Genomic Discoveries to Better Diagnostics and Therapies in Acute Leukemia \n\n\n\nBiosketch: Thoas Fioretos\, MD\, PhD\, is Professor of Clinical Genetics at Lund University and Senior Consultant at Skåne University Hospital. His research focuses on the molecular basis of acute leukemia and its translation into improved diagnostics and targeted therapies. His group applies genomic and single-cell approaches to define cell states\, stem-cell properties\, immune-evasion mechanisms and cell-surface targets. The group was among the first to establish IL1RAP as a therapeutic target on leukemia stem cells and recently identified SLAMF6 as an immune checkpoint in acute myeloid leukemia. These discoveries have supported antibody-based therapies\, including an investigator-initiated trial evaluating an IL1RAP-targeting antibody in AML and high-risk MDS at MD Anderson Cancer Center. Fioretos is a Wallenberg Clinical Scholar\, Platform Scientific Director of Clinical Genomics Lund at SciLifeLab and a founding member of Genomic Medicine Sweden. He is a member of the Royal Swedish Academy of Sciences and currently chairs its Class for Medical Sciences. \n\n\n\nAbstract: \n\n\n\n \n\n\n\n \n\n\n\n\nProgram\n\n\n\n08:45Registration and poster hangingPlease leave large bags and outerwear in the staffed Cloakroom09:00Doors open. Be seated at 09:1509:15Welcome by SciLifeLab Director Jan Ellenberg09:35Session 1: Immune Niches in CancerModerator: Anna DimbergA vascular perspective on immunity in cancer and inflammationGabriele Bergers\, VIB-KU Leuven Center for Cancer Biology\, BelgiumExploring the role of the anti-tumor immune response in tumor initiation and therapy response in melanomaGöran Jönsson\, Lund University\, SwedenFlash Talks10:45Coffee and Poster session (odd numbers)11:25Session 2: Tumor Microenvironment and Clinical TranslationModerator: Carina StrellFibroblast – Immune niches in health and diseaseAri Molofsky\, University of California\, San Francisco (UCSF)\, USEvoking Tumor Immunity in Immune-Resistant CancersAngelica Loskog\, Uppsala University\, Sweden and Lokon PharmaCAR T-cells: a powerful new immunotherapyGunilla Enblad\, Uppsala University and Uppsala University Hospital\, Sweden12:45Lunch13:45Session 3: Precision OncologyModerator: Jessica Nordlund & Panagiotis BaliakasEpigenetic memory in chronic lymphocytic leukemia: decoding the past predicts the futureIñaki Martin-Subero\, IDIBAPS\, SpainFrom Genomic Discoveries to Better Diagnostics and Therapies in Acute LeukemiaThoas Fioretos\, Lund University\, Sweden14:45Roundtable discussion: What is needed to translate Swedish cancer discoveries into clinical implementation?Moderator: Thuy TranPanelists: Gunilla Enblad\, Thoas Fioretos\, Maréne Landström\, Angelica Loskog\, Kristian Sandberg.Flash Talks15:15Coffee and Poster session (even numbers)15:55Session 4: Tumor Ecosystems and Spatial BiologyModerator: Aristidis MoustakasHighly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometryBernd Bodenmiller\, University of Zurich and ETH Zurich\, SwitzerlandNOX2-derived ROS as drivers of metastatic progressionAnna Martner\, University of Gothenburg\, Sweden16:50Best Poster Award and Closing wordJan Ellenberg\, Director\, SciLifeLabPoster Jury of SciLifeLab and DDLS Fellows17:00Meet-the-speaker and network mingle with snacks and beverages18:15End of SciLifeLab Science Summit\n\n\n\nProgram Science Summit 2026Download\n\n\n\nPoster session\n\n\n\nEveryone\, especially junior (PhD and postdoc) researchers are encouraged to participate with poster presentations and have the opportunity to win the Best Poster Award. \n\n\n\nDetails about the Poster session\nPoster Presentation Guidelines \n\n\n\nPoster Format \n\n\n\nThe poster boards are 103 cm wide and 143 cm high. \n\n\n\nMount your poster \n\n\n\nThe venue will be open from 8:45 AM. Please proceed to the 6th floor and hang your poster at your designated number. A numbered poster list will be provided closer to the event date. \n\n\n\nPoster sessions \n\n\n\nPoster Session I: During the morning coffee break\, presenters of posters with odd numbers (1\, 3\, 5\, 7…) should be present by their posters. \n\n\n\nPoster Session II: During the afternoon break\, presenters of posters with even numbers (2\, 4\, 6\, 8…) should be present by their posters. \n\n\n\nBest Poster Award \n\n\n\nAll poster presenters should attend the Best Poster Award ceremony at the end of the conference\, where the Best Poster Award will be announced. The Poster Jury will read the abstracts and evaluate the posters throughout the day based on (a) Quality of Science (b) Design (c) Capacity to explain the work. The Poster Jury will select the 2026 Science Summit Best Poster and award the winner a 5\,000 SEK Travel Grant (conditions apply). \n\n\n\nFlash Talks (5-min research pitch) selected from Abstracts. \n\n\n\nThe abstracts will be published on the event website and used to select Flash Talks (5-min research pitch).  \n\n\n\nDismount of posters \n\n\n\nPlease remove your poster immediately after the closing session at 5:00 PM. Poster screens will be collected at 5:30 PM\, and any remaining posters will be discarded. \n\n\n\n\nBest Poster Award\n\n\n\nThe Poster jury\, consisting of SciLifeLab Fellows\, will nominate the Science Summit 2026 Best Poster and award the winner a 5 000 SEK Travel Grant. \n\n\n\nSpread the word – download the flyer\n\n\n\nDigital sign_SS26_qrDownload\n\n\n\n\n\n\n\nPractical information\n\n\n\nTravel to Uppsala\n\n\n\nThe Venue\, Uppsala Konsert & Kongress (UKK) is next to the Train station. MAP here! Travel centres\, bus stops\, parking and hotels are all located within walking distance from Uppsala Konsert & Kongress. Several train and bus lines connect Uppsala to the rest of the country and the region\, and Arlanda Airport is only 18 minutes by train\, Stockholm Central station is approx. 30 minutes by train. \n\n\n\nUppland public transport (UL) timetables and information: www.ul.seStockholm public transport (SL) timetables and information: www.sl.se SJ timestables and information: www.sj.se \n\n\n\nGood to know\, travelling to Uppsala. \n\n\n\nParking\n\n\n\nThe nearest parking garage is Centralgaraget. There is also parking available in Kvarnens parking garage\, Svava\, S:t Per Gallerians garage\, Österplan\, and several other locations in central Uppsala. For more information about parking in the area\, please visit Uppsala Parkering. \n\n\n\nHotels in Uppsala\n\n\n\nFind suggestions for accommodation in Uppsala here \n\n\n\n\nImproved event experience: Introducing the Lyyti Event app \n\n\n\nThis event uses Lyyti for registration. Lyyti has launched the Lyyti Event app\, where you can find your Lyyti registration\, confirmation\, and ticket. You can also edit your information until the registration deadline. \n\n\n\nTo get started\, download “Lyyti Event” and sign up with the same email address you normally use for event registrations. The app only displays events associated with the email address used to create your account. \n\n\n\nIf you register for events using multiple email addresses\, your registrations will be split across separate app accounts. For the best experience\, please use one consistent email address for all Lyyti registrations. We hope this new functionality makes it easier for you to manage your participation. \n\n\n\n\nYou may also be interested in:\n\n\n\n\nThe PROMISE Initiative: Accelerating Cancer Innovation
URL:https://www.scilifelab.se/event/scilifelab-science-summit-2/
LOCATION:Uppsala Konsert & Kongress (UKK)\, Vaksala torg 1\, Uppsala\, 753 31\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2025/12/Hemsidan_feature-image-kopiera.jpg
ORGANIZER;CN="SciLifeLab Event":MAILTO:events@scilifelab.se
END:VEVENT
END:VCALENDAR